Standard of care

BD Named Among Fortune's Most Innovative Companies

Retrieved on: 
Tuesday, March 26, 2024
BDX, Patient, Marketing, Standard of care, Entrepreneurship, Creativity, Management

FRANKLIN LAKES, N.J., March 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2024 list of America's Most Innovative Companies .

Key Points: 
  • FRANKLIN LAKES, N.J., March 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2024 list of America's Most Innovative Companies .
  • "At BD, innovation is about a mindset of excellence and continuous improvement, boldly challenging ourselves to think ahead and partnering with our customers to understand the evolving needs of the billions of patients around the world who rely on our health care products and solutions," said Tom Polen, chairman, CEO and president of BD.
  • Fortune and Statista surveyed more than 35,000 employees from eligible companies and 8,000 industry experts to rank companies across the three categories, in addition to evaluating a company's patents within the product innovation category.
  • Of the more than 25,000 U.S. companies considered, those with the highest 200 scores were named to Fortune's list of America's Most Innovative Companies .

PathKeeper Surgical enters into know-how agreement with Mayo Clinic for low-radiation pediatric spine surgery

Retrieved on: 
Monday, March 25, 2024
MD, Radiation, Deformity, Machine learning, Mayo Clinic, KFAR, Research, Patient, Surgeon, Standard of care, Scoliosis, Safety, Dentistry

KFAR SABA, Israel, March 25, 2024 /PRNewswire/ -- PathKeeper Surgical, an Israeli medical technology company committed to advancing surgical solutions through innovative camera and machine learning technologies, announced it has entered into a know-how agreement with Mayo Clinic to research radiation levels in pediatric spine surgeries. The research will focus on reducing patient radiation exposure using minimally invasive optical navigation and utilizing intraoperative measurement tools for scoliosis correction, including vertebral body tethering.

Key Points: 
  • PathKeeper Surgical enters a know-how agreement with Mayo Clinic in Rochester, MN.
  • To address the unique challenges of pediatric patients undergoing spine surgery for scoliosis, Mayo Clinic pediatric spine surgeons Noelle Larson, MD, and Todd Milbrandt, MD, are collaborating with PathKeeper Surgical, a company widely known for its cutting-edge optical navigation that prioritize precision, safety, and minimization of radiation exposure.
  • "We are proud to collaborate with Mayo Clinic," said Erez Lampert, founder and Chief Executive Officer at PathKeeper Surgical.
  • The research and development efforts will include refining and expanding the application of PathKeeper's technology to tackle the unique challenges posed by pediatric spine surgery.

New treatment option for prostate cancer shows successful outcomes

Retrieved on: 
Saturday, March 23, 2024
Disease, Radiation, Cryotherapy, Hatred, Collateral damage, MRI, Prostate cancer, Average revenue per user, Urology, Heat, FASR, Risk, Patient, Lung, Neoplasm, Research, Cancer, Calcification, Standard of care, Radiology, Prostate, Society, Urinary incontinence, Kidney, Erectile dysfunction, PCA, PSA, UCLA, Urethra, Medical imaging

FAIRFAX, Va., March 23, 2024 /PRNewswire/ -- A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.

Key Points: 
  • "Prostate cancer is the most common form of cancer in men, affecting one in eight men in their lifetimes.
  • According to Dr. Raman, "This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency.
  • The latter are the complications of most prostate cancer therapies that patients hate and often result from a lack of precision in treatment monitoring."
  • Abstract #135 : Five-year outcomes after MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer.

Accushield and Serviam Collaborate to Combat Resident Loneliness in Senior Living

Retrieved on: 
Wednesday, March 20, 2024
Depression, Health, Prevalence, Caregiver, Network, Partnership, Pharmacy, Value, Social isolation, Standard of care, Attention, Volunteering, Quality of life, PBC, Ecosystem, Nursing, CSO, Loneliness, Management

Accushield and Serviam are committed to revolutionizing the landscape of senior care in America, placing resident well-being at the forefront, and fostering a sustainable financial future for senior living operators.

Key Points: 
  • Accushield and Serviam are committed to revolutionizing the landscape of senior care in America, placing resident well-being at the forefront, and fostering a sustainable financial future for senior living operators.
  • Serviam equips senior living operators to thrive within a value-based care framework by establishing a powerful ecosystem of technology and consultative services.
  • Accushield will partner with senior living communities and other engagement platforms to support seniors identified with low scores on the UCLA-3 Loneliness Scale.
  • "Through our partnership with Serviam, we are dedicated to combating loneliness in senior living communities," stated Charles Mann, Founder and CSO of Accushield.

HIMSS24: Linus Health Unveils Two New Evidence-Based, Digital Cognitive Screening Additions to its Comprehensive Brain Health Platform

Retrieved on: 
Monday, March 11, 2024
Research, Digital, Conference, Dementia, Confusion, Deficit spending, Alzheimer's disease, Patient, Linus, Triage, Standard of care, AI, MD, Ear, Hearing loss, MCI, Exhibition, Machine learning, Huber loss, Medicare, FDA, Hearing, Physician, Medical device

BOSTON, March 11, 2024 /PRNewswire/ -- Linus Health, a digital health company focused on enabling early detection of Alzheimer's and other dementias, announced today the expansion of its innovative, evidence-based suite of cognitive health assessments with the Hearing Screener and the Digital Trail Making Test Part B (dTMT). These essential additions to Linus Health's AI-enhanced digital cognitive assessment platform accelerate and simplify the early detection and management of mild cognitive impairment (MCI), a precursor to Alzheimer's Disease.

Key Points: 
  • These essential additions to Linus Health's AI-enhanced digital cognitive assessment platform accelerate and simplify the early detection and management of mild cognitive impairment (MCI), a precursor to Alzheimer's Disease.
  • Meanwhile, the Linus Health dTMT is rooted in an executive functioning assessment trusted for eight decades but now revolutionized through innovative AI, machine learning and digital health technologies.
  • "The Linus Health digital cognitive assessment platform continues to grow with practical tools to enable primary care physicians and specialists to easily adopt cognitive assessments as part of the standard of care.
  • Linus Health will demonstrate its new Hearing Screener and dTMT at the 2024 HIMSS Global Health Conference & Exhibition in Orlando, March 11-15.

EQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Retrieved on: 
Wednesday, March 13, 2024
UDH, CRC, German, Standard of care, Health, Union, Congress, DNA, Cancer, Pharmaceutical industry

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Key Points: 
  • Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    BERKELEY, US – MAINZ, Germany – March 12th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany.
  • Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.
  • For more details on Mainz Biomed’s participation in the UDH Congress and to learn about the Company’s innovative diagnostic solutions, please visit Mainz Biomed’s official website at mainzbiomed.com .

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 11, 2024
Fast Track, ICT, ICV, Research, WM, Indolent lymphoma, XSCID, NHL, ASH, FDA, Birmingham School of Law, City, Cancer, DSM-IV codes, Mustang, Sale, Nature, Tocilizumab, GBM, Standard of care, Safety, Dexamethasone, Society, University, Mayo Clinic, Clinical professor, Translation, University of Washington, Foreign investment, Tumor microenvironment, Associate, CRS, Patient, Clinical trial, Disease, Survival, CFIUS, Cytokine release syndrome, Follicular lymphoma, Pharmaceutical industry

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
  • Research and development expenses were $40.5 million for the year ended December 31, 2023, compared to $62.5 million for 2022.
  • 2023 and Recent Corporate Highlights:
    In July 2023, Mustang announced that it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc. (“uBriGene”) and closed the transaction.
  • In October 2023, Mustang completed a registered direct offering priced at-the-market for approximately $4.4 million in gross proceeds.

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Retrieved on: 
Monday, March 11, 2024
Diabetes, Senior, Randomized controlled trial, Inhalable insulin, RAA, Teaching, Hyperglycemia, MannKind Corporation, AUC, A1C, Standard of care, Conference, ATTD, Safety, University, MDI, Patient, Insulin, Automation, Clinical trial, T1D, Pharmaceutical industry

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Key Points: 
  • INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
  • “In this large, randomized trial utilizing more appropriate dose conversion, we are excited to see meal challenge results support the safety and efficacy of inhaled insulin from the start.”
    INHALE-3 is a 17-week randomized controlled trial with a 13-week extension.
  • Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label.
  • For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal (a 240 calorie nutritional shake) whereas those using usual care used RAA 5-15 minutes prior to the meal.

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

Retrieved on: 
Thursday, March 7, 2024
TMS, Mental health, TCN, Transcranial magnetic stimulation, TRD, Marketing, FDA, Quality of life, Hope, Standard of care, STIM, Depression, Patient, DSM-IV codes, Mental, MDD, Partnership

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers.

Key Points: 
  • MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers.
  • Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.
  • "Transformations Care Network's alliance with NeuroStar is more than a milestone; it is a tangible manifestation of our vision to integrate the most advanced treatments in our suite of services," said Brian Wheelan, Chief Executive Officer at Transformations Care Network.
  • To learn more about Transformations Care Network, visit www.transformationsnetwork.com .

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.